Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
Saved in:
| Title: | Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. |
|---|---|
| Authors: | Gonzales D (AUTHOR), Rennard SI (AUTHOR), Nides M (AUTHOR), Oncken C (AUTHOR), Azoulay S (AUTHOR), Billing CB (AUTHOR), Watsky EJ (AUTHOR), Gong J (AUTHOR), Williams KE (AUTHOR), Reeves KR (AUTHOR), Varenicline Phase 3 Study Group (CORPORATE AUTHOR), Gonzales, David1 (AUTHOR), Rennard, Stephen I (AUTHOR), Nides, Mitchell (AUTHOR), Oncken, Cheryl (AUTHOR), Azoulay, Salomon (AUTHOR), Billing, Clare B (AUTHOR), Watsky, Eric J (AUTHOR), Gong, Jason (AUTHOR), Williams, Kathryn E (AUTHOR) |
| Source: | JAMA: Journal of the American Medical Association. 7/5/2006, Vol. 296 Issue 1, p47-55. 9p. |
| Database: | Academic Search Ultimate |
| ISSN: | 00987484 |
|---|---|
| DOI: | 10.1001/jama.296.1.47 |
